BioSpace News Archive

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical data on the therapeutic potential of its lead anti-miR for the treatment of nonalcoholic steatohepatitis (NASH), at the EASL International Liver Congress™ 2019 being held April 10-14, 2019 in Vienna,

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) that was held on April 1 – 4, 2019 in Ottawa, Canada

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company’s Scientific Advisory Board.

Henry Schein, Inc. (Nasdaq: HSIC) demonstrated its commitment to expanding access to health care and developing high-level capabilities in oral health leaders from around the world by sponsoring the Senior Dental Leaders Programme for a 13th year

New freeze-dried, Qscript lyo 1-step offers greater sensitivity, stability and portability compared to currently available liquid master mixes

Use of ready-to-infuse bags eliminates steps in the complex chemotherapy preparation process, reducing exposure and mitigating inherent provider and patient safety risks

Lianluo Smart Limited is a China based professional smart service and products provider announced recently that a health sciences company invested by Lianluo Smart was successfully listed on the Nasdaq Stock Market on April 5th, 2019.

The SanBio Group announced that SB623, a regenerative cell therapy that the Group is developing globally for the treatment of chronic motor deficit resulting from traumatic brain injury (TBI), has received the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare (MHLW) of Japan.

CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company to European investors, Monday, April 8, 2019, at the H.C. Wainwright Global Life Sciences Conference 2019 in London, England.

Merger combines more than 30 years of patient-centered expertise to Empower Everyone, Ignore No One